DexCom, Inc. (DXCM) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 78.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,409 shares of the medical device company’s stock after selling 19,185 shares during the period. Oppenheimer Asset Management Inc.’s holdings in DexCom were worth $265,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Advisor Group Inc. boosted its stake in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 837 shares in the last quarter. IFP Advisors Inc raised its holdings in DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after buying an additional 568 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in DexCom by 9.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after buying an additional 250 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after buying an additional 354 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new position in DexCom in the 2nd quarter valued at approximately $249,000.

A number of research analysts recently issued reports on DXCM shares. Jefferies Group reiterated a “buy” rating and issued a $91.00 price objective on shares of DexCom in a report on Thursday, September 28th. BMO Capital Markets reiterated a “buy” rating and issued a $90.00 price objective on shares of DexCom in a report on Friday, September 8th. Canaccord Genuity reiterated a “buy” rating and issued a $90.00 price objective on shares of DexCom in a report on Tuesday, August 22nd. Stephens reiterated a “buy” rating and issued a $70.00 price objective (down previously from $83.00) on shares of DexCom in a report on Thursday, September 28th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $87.00 price objective on shares of DexCom in a report on Thursday, September 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $71.36.

DexCom, Inc. (NASDAQ DXCM) opened at $57.04 on Monday. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom, Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $88.80.

In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $69.81, for a total transaction of $101,224.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $58.85, for a total transaction of $353,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,955 shares of company stock valued at $2,583,643. Company insiders own 1.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) Shares Sold by Oppenheimer Asset Management Inc.” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://sportsperspectives.com/2017/12/18/dexcom-inc-dxcm-shares-sold-by-oppenheimer-asset-management-inc.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply